Company Overview and News

 
Cardinal Namdini Pre-Feasibility Study 4.76 Moz Ore Reserve

2018-09-18 globenewswire
TORONTO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX / TSX: CDV) (“Cardinal” or “the Company”) is pleased to announce the results of its Preliminary Feasibility Study (“PFS”) for the Namdini Gold Project (“Namdini”) in Ghana, West Africa.
IFK IFX MALRY MALRF CDV MIN CDV CDNL

 
Cardinal Successfully Finalises US$25M Sprott Facility

2018-08-22 globenewswire
TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX/TSX: CDV) (“Cardinal” or “the Company”) is pleased to advise that all legal and formal documentation with Sprott Private Resource Lending (Collector), L.P. (“Sprott”) to provide a US$25 million (A$32 million) senior secured credit facility (“Facility”) has been successfully completed.
SII CDV CDV CDNL

2
Quarterly Activities Report for the Period Ended 30 June 2018

2018-07-31 globenewswire
TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX:CDV) (TSX:CDV) (“Cardinal” or “the Company”), an African gold focused exploration company, is pleased to present to shareholders its Quarterly Activities report for the period ended 30 June 2018. Currently Cardinal holds four tenements within the Bolgatanga Project, with Subranum comprised of a single tenement in central Ghana (Figure 1).
IFK IFX KGC MALRY K MALRF CDV MIN CDV CDNL

 
Cardinal Executes US$25 Million Term Sheet With Sprott

2018-07-31 globenewswire
TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX/TSX: CDV) (“Cardinal” or “the Company”) is pleased to announce it has received investment committee approval from and executed a term sheet with Sprott Private Resource Lending (Collector), L.P. (“Sprott”) to be provided with a US$25 million senior secured credit facility (“Facility”). The Facility is subject to mutually satisfactory documentation and other customary conditions precedent, which are expected to be completed on or about 17 August 2018.
SII CDV CDV CDNL

2
Cardinal Makes New Gold Discovery at Ndongo

2018-07-16 globenewswire
TORONTO, July 16, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX:CDV) (TSX:CDV) (“Cardinal” or “the Company”) is pleased to announce that it has intersected further gold at a new discovery named Ndongo East on its 100% owned Ndongo License, located approximately 15 km north of the Company’s flagship Namdini Gold Project which has a 6.5 Moz Indicated Mineral Resource (Figure 1).
KGC MALRY K MALRF CDV MIN CDV CDNL

12
Encouraging First Pass Gold Results at Ndongo

2018-05-27 globenewswire
TORONTO, May 27, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX:CDV) (TSX:CDV) (“Cardinal” or “the Company”) is pleased to announce that it has received encouraging results from its first pass shallow RC drilling designed to test one of the six coincident gold-in-soil and geophysical targets on the Ndongo License within the Bolgatanga Project, which is located ~15 km north of the Company’s Namdini Gold Project with an Indicated Mineral Resource of 6.
KGC MALRY K MALRF CDV MIN CDV CDNL

1
Technical Report on Namdini Gold Project Filed on SEDAR

2018-04-18 globenewswire
TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Cardinal Resources Limited (ASX/TSX: CDV) ("Cardinal" or the "Company") is pleased to announce that it has filed a National Instrument 43-101 ("NI 43-101") Technical Report in respect of the Mineral Resource Estimation announced on 5 March 2018.
CDV CDV CDNL

12
First Pass Regional Exploration Drilling Underway

2018-04-04 globenewswire
• Cardinal’s commitment to regional exploration in Ghana has been stepped up on the strength of early results, with drill rigs testing a range of targets across the extensive tenement package
KGC MALRY K MALRF CDV MIN ABZUF CDV CDNL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CDV / Com Dev Intl on message board site Silicon Investor.

GCDV -- gcdv -- Grace Development Inc. GCDV -- gcdv -- Grace Development Inc. GCDV -- gcdv -- Grace Development Inc. Com Dev CDV.T Com Dev CDV.T Com Dev CDV.T
Com Dev International: wireless u0026 satellite communications Com Dev International: wireless u0026 satellite communications Com Dev International: wireless u0026 satellite communications